Olmesartan

1 paper1 finding

PubChem 158781 ChEBI 48416

Outcomes

1

Cardio-ankle vascular index

downin humans1

1 study

Olmesartan decreases cardio-ankle vascular index in humans.
“Angiotensin II receptor blocker, olmesartan decreased CAVI much more than that of calcium channel antagonist, amlodipine”
Reviewcompared to amlodipine
Evaluation of blood pressure control using a new arterial stiffness parameter, cardio-ankle vascular index (CAVI)
Current hypertension reviews1 Feb 2013

More on Cardio-ankle vascular index

Latest

1 in 12 months

American Journal of Preventive Cardiology5 Oct

Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension

Trial in 546 peopleGLP-1 receptor agonists

Current Hypertension Reviews1 Feb

Evaluation of blood pressure control using a new arterial stiffness parameter, cardio-ankle vascular index (CAVI)

ReviewCardio-ankle vascular index